Laurus Labs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,206 Cr +33.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
LL

Laurus Labs Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Laurus Labs Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,812Cr
+5.3% YoY
+1.9% QoQ
Net profit
₹282Cr
+21% YoY
+11.9% QoQ
Margin
28%
+4 pp YoY
+1 pp QoQ
Price₹2,034
Market cap₹1.1L Cr
P/E96.6

The short version

Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand. Laurus Labs expects strong growth in CDMO segment with good year-on-year growth in FY '27, despite possible quarter-to-quarter lumpiness.

From Laurus Labs Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

  • Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand.
  • CDMO revenues are projected to grow to 50% of total sales by FY2030, indicating significant expansion in this segment.
  • The Affordable Medicines division (formerly Generics) showed strong 18% growth in FY26, with steady business outlook.
  • Fluctuations quarter-to-quarter possible, but overall growth momentum is expected to be maintained, especially in CDMO.
  • New fermentation and formulation capacities coming online will support volume expansion.

2 more points from Laurus Labs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Laurus Labs is investing in new modalities including cell culture, precision fermentation, enzymes, biocatalysis, cell therapy, gene therapy, and ADCs as a strategic focus (Page 17).
  • A new greenfield capex of 500 acres in Atchutapuram is planned; more details to be shared next quarter (Page 17).
  • Capex increased from INR 1,000 crores annually to INR 1,500 crores annually, reflecting growth and with good visibility into product and customer demand (Page 16).

2 more points from Laurus Labs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Laurus Labs has a strong order book for the next year, ensuring continued growth.
  • Visibility exists for commercialization of some CDMO programs in FY '27, but due to clinical uncertainties, exact timing is hard to predict.
  • Orders are diversified across multiple products, minimizing concentration and destocking risks.

2 more points from Laurus Labs Ltd's call on order book

Create a free account to keep reading this call

Laurus Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Laurus Labs Ltd Q4 FY26 results — key figures

Laurus Labs Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,8121,720+5.3%1,778+1.9%
Operating profit (EBITDA)512421+21.6%480+6.7%
Operating margin28%24%+4 pp27%+1 pp
Profit before tax361312+15.7%327+10.4%
Net profit (PAT)282233+21%252+11.9%
EPS (₹)5.174.33+19.4%4.66+10.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.2K Cr, net profit ₹436 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Laurus Labs Ltd Q4 FY26 results?

Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand. Laurus Labs expects strong growth in CDMO segment with good year-on-year growth in FY '27, despite possible quarter-to-quarter lumpiness.

What is Laurus Labs Ltd share price analysis?

Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 96.6 with a market cap of ₹105,577 Cr. Investors should review the full earnings analysis for detailed insights.

Is Laurus Labs Ltd planning capital expenditure?

Laurus Labs is investing in new modalities including cell culture, precision fermentation, enzymes, biocatalysis, cell therapy, gene therapy, and ADCs as a strategic focus (Page 17).

Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.